Odyssey Health provides update on concussion drug program; Phase I trial completed, safety shown

Odyssey Health, Inc.

Completed FDA-required Phase I human clinical trial; drug safe, well tolerated, no accumulation over 10 days.
Raised over $5M in funding; access to Lincoln Park equity line of up to $10M.
Added two key executives with pharmaceutical drug development experience to management.
Filed patent application for novel breath-propelled intranasal delivery device.
Developed nanoparticle spray-dried formulation in partnership with UK partner under GMP.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.